The decision. Should GI/GL be a marker you steer diet by, alongside (or instead of) fibre and whole-grain content? GI = how much 50 g of carbohydrate in a food raises postprandial blood glucose vs a glucose/white-bread standard; GL = GI x the carbohydrate amount. Single primary source (Jenkins 2024, gold MA), confidence: low — and read the whole page through the source’s provenance: its lead author invented the GI and the paper is an explicit rebuttal to the WHO/Reynolds conclusion that GI has «little relevance» (see Guidance divergence below).

The associations are real and consistent, mostly GRADE-low

Jenkins pooled 10 mega-cohorts (>=100 000 each, Richard Doll Consortium), highest-vs-lowest quantile, most-adjusted, fixed-effects. High GI tracks higher risk across all four main outcomes; GL matches GI for T2D and CVD but not cancer/mortality.

Exposure -> outcomeRR (95% CI)I2GRADE / NutriGrade
GI -> type 2 diabetes1.27 (1.21-1.34)71%low / moderate
GI -> total CVD1.15 (1.11-1.19)35%low / moderate
GI -> all-cause mortality1.08 (1.05-1.12)90%low / moderate
GI -> diabetes-related cancer1.05 (1.02-1.08)23%low / moderate
GL -> type 2 diabetes1.15 (1.09-1.21)60%
GL -> total CVD1.15 (1.10-1.20)38%
GL -> cancer / mortalityNS or inverse

(Jenkins et al., 2024)

  • The one GRADE-moderate cell is GI -> CVD mortality 1.14 (1.08-1.21); GI -> CHD mortality 1.33 (1.14-1.55) and stroke mortality 1.29 (1.10-1.50) are the largest components. NutriGrade (used deliberately because «GRADE might not adequately assess … prospective cohort dietary assessments») rates the mains moderate — so the certainty verdict itself depends on the instrument chosen.
  • These are relative risks on a modest absolute base. For most outcomes the extreme-quantile RR is 1.05-1.15; the decision-weight is small except for the T2D 1.27 arm. E-values exceeded 1.2 (robust to a moderate unmeasured confounder) for the main GI/GL outcomes except GI/GL -> cancer and GL -> mortality. (Jenkins et al., 2024)

Independent lever, or a proxy for the carb-quality pattern? (the crux)

Jenkins’ headline is that low-GI associations are «similar to those for low GI diets» for fibre and whole grains in the same cohorts, and reads this as validating GI as a carbohydrate-quality predictor. The wiki’s read is more cautious — the same data are as consistent with GI being a proxy:

  • The markers are collinear. «foods high in carbohydrates also tend to have a high GI» (Jenkins et al., 2024) — GI, GL, fibre and whole-grain content ride together in whole-food diets, so near-identical associations are exactly what proxies of one underlying pattern produce.
  • The mutual adjustment is too sparse to separate them. «only 12 (17%) of the 69 GI main outcome assessments controlled for fibre, controlling for fibre or not made little difference»; no fibre or whole-grain assessment controlled for GI. (Jenkins et al., 2024) little difference on 17% is weak evidence of independence, not the mutually-adjusted test that would settle it.
  • This is the Is the Food Category Doing Any Work question applied to a construct: similar magnitude + shared cohorts + shared confounding + minimal cross-adjustment cannot attribute the effect to GI rather than the fibre/whole-grain/low-refined-carb pattern that carries it. (inferred from Jenkins et al., 2024)

Direction has human-corroborated mechanistic support (so this is not a GI does nothing verdict): postprandial glucose excursions -> oxidative stress/free radicals -> insulin resistance and vascular dysfunction (Ceriello, Monnier), and acarbose RCTs (STOP-NIDDM, ACE) — which pharmacologically create a low-GI diet «without other dietary changes» — cut incident T2D. (Jenkins et al., 2024) That is a directional mechanism, not outcome-proof that steering food GI moves events independently of fibre.

Why the estimate is fragile — measurement error, twice over

GI/GL inherit FFQ error (Measurement Error in Dietary Assessment) plus GI-table assignment error (Atkinson 2008 tables mapped onto FFQ foods; local tables for Asian FFQs; PURE bread-scale converted). And the studied contrast is narrow: lowest-quantile mean GI 58, highest 67 (glucose scale), which the authors attribute to «a small range of low GI and GL values, possibly related to health-conscious individuals». (Jenkins et al., 2024) A narrow, error-laden contrast attenuates a real gradient toward the null and makes any dose-response knee unlocatable — consistent with the wiki’s The Underivable Optimum reading. No plateau/knee was located; monotone «over the studied range» only.

Guidance divergence — a certainty-grading dispute, not a data clash

The 2019 WHO-sponsored Reynolds/Mann series and the 2023 WHO carbohydrate guideline endorsed fibre and whole grains but held «GI … was not considered to be a relevant dietary factor for the prevention of chronic diseases». (Jenkins et al., 2024) Jenkins calls that «counterintuitive» and this MA is the rebuttal. But this is largely NOT a dispute about the associations — Jenkins notes the WHO appendix itself carried significant GI associations. It is a disagreement about whether GRADE-low cohort evidence is strong enough to act on (GRADE downgrades observational data; NutriGrade, which Jenkins co-develops, does not), plus a live conflict of interest (the GI’s inventor, ICQC co-chair, IDF-guideline author, extensive food-industry funding). Not filed as a joined tension (the not-joined check: same evidence base, different certainty threshold) — see the G-gap. (inferred from Jenkins et al., 2024)

Decision relevance

  • GI/GL is not a separate big rock. On this evidence, steering by fibre and whole-grain content captures most of what steering by GI would, because the markers are collinear and GI’s independent contribution is unproven. The practical advice — more whole grains, legumes, intact/minimally-refined carbohydrate, fewer refined/sugary carbs — is the same one fibre and whole grains already yield.
  • The T2D and CVD-mortality arms are the ones with any decision weight (RR 1.27 and 1.14, moderate where anything is); cancer and GL-mortality are the softest (E-value <1.2, GL inverse/null).
  • Where GI plausibly adds is a stratum signal, not a population lever: the impaired-glucose / insulin-resistant, where postprandial excursions and the acarbose RCTs bite -> Carbohydrate Restriction and Type 2 Diabetes Remission, Continuous Glucose Monitoring as a Health Intervention.

Certainty and gaps

  • confidence: low — single primary source, deeply-conflicted lead author, GRADE-low mains, an unresolved proxy-vs-lever question, and a narrow error-laden exposure contrast. The magnitudes are sound (gold MA); the reframe (GI as an independent carb-quality lever) is not established.
  • Gaps (G): the mutually-adjusted GI-net-of-fibre-and-wholegrain test the independence claim needs is largely absent (only 17% adjusted for fibre); no long-term GI RCT on hard outcomes (acarbose is the pharmacological proxy); the WHO/Reynolds GI-dismissal is not extracted as its own claim, so a clean joined tension is deferred to a Revisit.

Self-critique [run 2026-08-13, before commit]

  • Food-category launder check (the guard for this ingest). The page does not credit GI when fibre/whole-grain/matrix may be the actor — the crux section leads with the proxy reading and tags the independence doubt as the wiki’s. No [E-independent] claimed (there is one primary source).
  • Over-claim. No superlative scoped to the vault’s holdings; the source’s own reframe is reported as the authors’ interpretation and explicitly not adopted. The RRs are extracted, the proxy reading is .
  • Symmetric standards. The magnitudes are held even though they run with a plausible mechanism; the reframe is discounted for COI and the wiki flags the source’s convenient asymmetry (a confounder invoked only for the disconfirming GL-cancer arm). The conflict does not delete the pooled numbers.
  • Not-joined / counter-passage. The GI-vs-WHO clash was checked and found to be a certainty-grading disagreement over shared evidence -> recorded as a distinction, no tension filed.

References

Jenkins, D. J. A., Willett, W. C., Yusuf, S., Hu, F. B., Glenn, A. J., Liu, S., Mente, A., Miller, V., Bangdiwala, S. I., Gerstein, H. C., Sieri, S., Ferrari, P., Patel, A. V., McCullough, M. L., Le Marchand, L., Freedman, N. D., Loftfield, E., Sinha, R., Shu, X.-O., … Yang, W. (2024). Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants. The Lancet Diabetes &amp; Endocrinology, 12(2), 107–118. https://doi.org/10.1016/s2213-8587(23)00344-3